An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Lupartumab amadotin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bayer
- 13 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 13 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 12 May 2016 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.